Global Nucleic Acid Drugs Market Insights, Forecast to 2031

The global Nucleic Acid Drugs market is projected to grow from US$ 14636 million in 2024 to US$ 21722 million by 2031, at a Compound Annual Growth Rate (CAGR) of 7.43% during the forecast period.

The North America market for Nucleic Acid Drugs is estimated to increase from $ 8327.53 million in 2024 to reach $ 11827 million by 2031, at a CAGR of 6.4% during the forecast period of 2025 through 2031.

The China market for Nucleic Acid Drugs is estimated to increase from $ 81.1 million in 2024 to reach $ 1231.84 million by 2031, at a CAGR of 44.83% during the forecast period of 2025 through 2031.

The Europe market for Nucleic Acid Drugs is estimated to increase from $ 3316.94 million in 2024 to reach $ 6063.24 million by 2031, at a CAGR of 10.64% during the forecast period of 2025 through 2031.

The global key companies of Nucleic Acid Drugs include Sarepta Therapeutics, Ionis Pharmaceuticals, Alnylam, Biogen, Nippon Shinyaku, Sobi, Novartis, BioNTech, Pfizer, Moderna Therapeutics, etc. In 2024, the global top five players had a share approximately 86.47% in terms of revenue.

Report Includes

This report presents an overview of global market for Nucleic Acid Drugs market size. Analyses of the global market trends, with historic market revenue data for 2020 - 2024, estimates for 2025, and projections of CAGR through 2031.

This report researches the key producers of Nucleic Acid Drugs, also provides the revenue of main regions and countries. Highlights of the upcoming market potential for Nucleic Acid Drugs, and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Nucleic Acid Drugs revenue, market share and industry ranking of main companies, data from 2020 to 2024. Identification of the major stakeholders in the global Nucleic Acid Drugs market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2020 to 2031. Evaluation and forecast the market size for Nucleic Acid Drugs revenue, projected growth trends, production technology, application and end-user industry.

Descriptive company profiles of the major global players, including Sarepta Therapeutics, Ionis Pharmaceuticals, Alnylam, Biogen, Nippon Shinyaku, Sobi, Novartis, BioNTech, Pfizer, Moderna Therapeutics, etc.

Market Segmentation

By Company

On Market Company

Sarepta Therapeutics

Ionis Pharmaceuticals

Alnylam

Biogen

Nippon Shinyaku

Sobi

Novartis

BioNTech

Pfizer

Moderna Therapeutics

Jazz Pharmaceuticals

Novo Nordisk

AstraZeneca

Astellas Pharma

On Pipeline Company

CureVac

Regulus Therapeutics

ProQR

Secarna

MiNA Therapeutics

Sylentis

Arrowhead

Silence Therapeutics

Segment by Type

Antisense Oligonucleotides (ASO)

siRNA

mRNA

Segment by Application

Neuromuscular Diseases

hATTR

COVID-19

Other

By Region

North America

United States

Canada

China

Asia-Pacific

Japan

South Korea

Southeast Asia

India

Australia

Rest of Asia

Europe

Germany

France

U.K.

Italy

Russia

Rest of Europe

Latin America

Mexico

Brazil

Rest of Latin America

Middle East & Africa

Middle East

Africa

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Revenue of Nucleic Acid Drugs in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. This section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Nucleic Acid Drugs companies’ competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by Type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by Application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: North America (US & Canada) by Type, by Application and by country, revenue for each segment.

Chapter 7: Europe by Type, by Application and by country, revenue for each segment.

Chapter 8: China by Type, and by Application, revenue for each segment.

Chapter 9: Asia (excluding China) by Type, by Application and by region, revenue for each segment.

Chapter 10: Middle East, Africa, and Latin America by Type, by Application and by country, revenue for each segment.

Chapter 11: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Nucleic Acid Drugs revenue, gross margin, and recent development, etc.

Chapter 12: Analyst's Viewpoints/Conclusions Show more